Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.
We compared survival from HIV-1 seroconversion before and during the periods of highly-active antiretroviral therapy (HAART). Survival expectations were substantially better for HIV-1-infected individuals in 1997-98 (HAART period) compared with those in 1986-96 (pre-HAART period). Estimated survival 10 years from seroconversion was also substantially better in the later period.
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality*; D006679:HIV Seropositivity / Q000401:mortality; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D015996:Survival Rate; D013997:Time Factors
D019380:Anti-HIV Agents